Albert David share price, P/E, ROE & financials

Albert David (ALBERTDAVD) had a P/E of 19.7× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 16% below their 52-week high. Sales fell 1.1% a year over 3 years; its ROCE of 0.8% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 0.6%. It is a small-cap company with a market cap of ₹444 Cr, ranked 82nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 12% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹767.00
Day high: ₹788.30
Day low: ₹760.20
Prev. close: ₹773.00
Volume: 1.4K

Health check

1 good · 5 to check

ReturnsBehind
−11.9% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 19.7 vs industry 28.7.
GrowthShrinking
Sales −1.1% a year over 3 years.
ProfitabilityWeak
ROCE 0.8% vs peer median 17.9%.
Balance sheetStretched
Debt 0.08× equity, interest covered 1.2×, Piotroski 1 of 9.
Red flags1 to check
Return on equity is low at −0.4%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹444 Cr, #82 of 154 in its industry by size.

Defensive

Beta 0.41 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹364 Cr · profit ₹23 Cr

Market cap: ₹444 Cr; Small cap
P/E: 19.7; Industry 28.7
Price to book: 1.13; Peers 4.99
Dividend yield: 0.64%
ROE: −0.4%; Peers 14.7%
ROCE: 0.8%; Peers 17.9%
Debt to equity: 0.08; Debt ₹30 Cr
EPS (TTM): ₹39.53; Face value ₹10
OPM (TTM): 6.8%; Net margin 6.2%
Sales growth: +43.6%; Latest quarter vs a year ago
Profit growth: +303.1%; Latest quarter vs a year ago
Price to sales: 1.22; EV/EBITDA 8.1

Strengths

Practically debt-free.
Quarterly profit up 303.1% on a year ago.
Quarterly sales up 43.6% on a year ago.
P/E of 19.7 against an industry P/E of 28.7.

Risks to check

Return on equity is low at −0.4%.

Derived automatically from reported figures. Not a recommendation.

About Albert David

Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, and vision care products. The company exports its products to Latin American, South East Asian and North African countries Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.

Headquarters: Kolkata
Employees: 1,476
Sector: Healthcare
ISIN: INE155C01010
Website: albertdavidindia.com

Price range

52 weeks

₹579.90₹931.85

Today

₹760.20₹788.30

Avg volume (3M): 6K
1-year return: minus 11.9%
From 52-week high: minus 16.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
ALBERTDAVDAlbert David	778.60	plus 0.72%	444	19.7	1.13	0.8%	−0.4%	7.3%	−1.1%	–	0.64%	minus 11.9%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
70.6	87.2	89.9	85.9	101
81.2	86.8	79.1	83.1	90.7
−10.7	0.4	10.8	2.8	10.6
−15.1%	0.5%	12.0%	3.2%	10.5%
22	0	12.4	−24.8	28
0.6	0.8	0.9	0.4	0.5
2.4	2.2	2.4	2.7	2.3
8.4	−2.6	19.9	−25.2	35.8
5.9%	−27.9%	23.1%	15.1%	10.6%
7.9	−3.3	15.3	−21.4	32
13.91	-5.79	26.81	-37.56	56.07

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −1.1%
ROE: −0.4%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
340	360	343	329
–	+6.0%	minus 4.7%	minus 4.0%
295	312	339	319
45.1	47.9	4.2	9.9
13.3%	13.3%	1.2%	3.0%
10.7	10.2	9.2	6.2
0.3	0.2	0.3	2.5
8.5	6.8	7	9.8
3.8	46.3	19.2	−3.2
50.7	97.3	25.2	0.5
28.7%	22.5%	31.8%	384.8%
36.2	75.4	17.2	−1.5
–	+108.5%	minus 77.2%	minus 108.7%
63.39	132.15	30.14	-2.62

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
5.7	5.7	5.7	5.7
306	377	387	386
5.3	3.3	12.3	29.6
107	112	107	98
423	498	511	519
83.1	88.7	99.8	121
9.2	10.7	5.8	25.9
25.9	32.8	54	19.8
203	285	244	258
102	80.5	108	94.5
423	498	511	519

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
10.5	45.5	−28.4	−7.7
−5	−33.2	23.3	−4.4
−6.4	−8.3	0.1	11.9
−0.8	4	−5	−0.1
−5.2	−10.9	−14.9	−29.1
5.3	34.6	−43.3	−36.8
−5.1	−5.2	−6.5	−2.9

Shareholding pattern

Source: NSE filings

62.2%

promoters

Promoters62.24%
Public37.76%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	62.24%	37.76%	0.00
30 Jun 2026	62.24%	37.76%	0.00
31 Mar 2026	62.24%	37.76%	0.00
31 Dec 2025	62.24%	37.76%	0.00
30 Sep 2025	62.24%	37.76%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you